You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華檢醫療(01931.HK)年度淨利2.1億元 同比增加20.3%
格隆匯 03-17 22:54

格隆匯3月17日丨華檢醫療(01931.HK)公吿,截至2022年12月31日止年度業績,公司實現收益27.49億元,同比增加0.7%;母公司擁有人應占溢利2.1億元,同比增加20.3%;每股盈利15.61人民幣分。董事會建議從公司股份溢價賬撥資向公司股東派付截至2022年12月31日止年度的末期股息每股普通股5.556港仙,惟須待股東於應屆股東周年大會上通過普通決議案批准。

溢利增長主要歸因於(i)毛利率增加;(ii)根據於2020年5月19日公司採納的股份獎勵計劃,以股份支付僱員報酬福利有關的開支由截至2021年12月31日止年度的人民幣3855.5萬元下降至報吿期間的人民幣1199.3萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account